Collegium Pharmaceutical (COLL) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed Collegium Pharmaceutical (COLL) over the past year, gaining 5.3% versus a loss of 33.5%. Over five years, ZVRA leads with a +16.6% price change compared with +5.3% for COLL. Collegium Pharmaceutical is the larger company by market cap ($719.2 million vs $676.4 million), about 1.1 times the size.
On valuation, Collegium Pharmaceutical trades at a lower forward P/E (3.3x vs 10.6x for Zevra Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | ZVRA |
|---|---|---|
| Share price | $22.09 | $11.39 |
| Market cap | $719.15M | $676.38M |
| 1-day change | -0.09% | +3.55% |
| YTD return | -52.29% | +27.12% |
| 1-year return | -33.48% | +5.27% |
| 5-year return | +5.29% | +16.58% |
| P/E ratio (TTM) | 17.39 | 11.99 |
| Forward P/E | 3.33 | 10.58 |
| EPS (TTM) | $1.27 | $0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.79 | $15.04 |
| 52-week low | $21.43 | $8.01 |
| Distance from 52-week high | -56.50% | -24.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +121.82% | +119.49% |
| Average volume | 751.71K | 1.09M |
| Shares outstanding | 32.56M | 59.38M |
| Employees | 423 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZVRA has outperformed COLL by 38.8 percentage points over the past year.
- Collegium Pharmaceutical trades at a higher earnings multiple (17.4x vs 12.0x trailing P/E).
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
COLL vs ZVRA FAQ
Which is bigger, Collegium Pharmaceutical or Zevra Therapeutics?
Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $719.15M compared with $676.38M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, COLL or ZVRA?
ZVRA returned +5.27% over the past 12 months, compared with -33.48% for COLL (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, COLL or ZVRA?
ZVRA has the lower trailing P/E at 12.0, versus 17.4 for COLL. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Collegium Pharmaceutical and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.